Visit Website http://care52.com Contact Me
My Company Care52

Role(s) in Healthcare Innovation:

Entrepreneur Investor

Atul Kumar, MD, MBA

Physician

Care52

North Hills, New York United States


Emory, UNC-Chapel Hill
Physician

About Me

I am a physician by training with 25 years of clinical experience in ER/urgent care medicine; the last 15 as a gastroenterologist. Alongside, I have had an interest in AI and HIT over 15 years, having developed expert diagnostic systems for complex conditions in with collaborators at school of Applied Math at Stony brook University. I also currently have a portfolio of investments spanning healthtech. I am a frequent speaker at national conferences on AI in Medicine. I have served in various roles including heading divisional development at a University Medical Center, Senior Faculty at Medical University, TEDMED scholar, GI FDA Adcom, member of the MedStartr Investment Review Committee, advisor to various startups including HIT and device companies.

I am looking for healthcare innovations:

No project created yet. Lets change that!
Discover Projects

No comments on any project yet. Lets change that!
Discover Projects

No likes on any project yet.. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No project reviewed yet. Lets change that!
Discover Projects

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.